

Provisional 2023 EPHMRA ATC Developments

The following new class structures were voted on by EPHMRA/Intellus in May/June 2022 and agreed in principle. These structures will now be used in the next part of the development process which is the detailed refinement of the rules.

Please note that these new class structures are provisional at this time. The 2023 codes, descriptions and Guideline text will be finalised and published by the Committee at the end of 2022. The new structures then come into effect from the beginning of 2023.

Platelet-enhancing products

New grouping of platelet-enhancing products to include thrombopoietin agonists (current class B2E) and other substances such as the thrombopoietic growth factor oprelvekin.

B2E	PLATELET-ENHANCING PRODUCTS
B2E1	Thrombopoietin agonists
	Includes products containing thrombopoietin agonists for thrombocytopenia, eg avatrombopag, eltrombopag, lusutrombopag, romiplostim, etc.
B2E9	Platelet-enhancing products, other
	Includes products for thrombocytopenia containing fostamatinib, oprelvekin, etc.

HIV antivirals – multiclass combinations

New fourth level class for products containing different types of HIV antiviral (these are currently in J5C9).

J5C8	HIV antivirals, multiclass combination products
	Includes products containing two or more substances from different HIV subclasses. For example, an integrase inhibitor in combination with a nucleoside reverse transcriptase inhibitor. Combinations of HIV antivirals from a single class are classified in that relevant specific class, eg a product containing only nucleoside reverse transcriptase inhibitors is classified in J5C1.